Agenda of the CHMP meeting 16-19 September 2024

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Date of authorisation: 23/02/2004, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Bondronat, ibandronic acid, Date of authorisation: 25/06/1996, Revision: 34, Status: Authorised

IRIS guide for applicants - How to create and submit scientific applications, for industry and individual applicants

Healthcare professionals: Key documents

Early dialogue with healthcare professional organisations for marketing authorisation applications: 1-year report

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Date of authorisation: 10/11/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), Date of authorisation: 17/12/2020, Revision: 6, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Uplizna, Inebilizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0513/2023

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 60, Status: Authorised